Publication: Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Yalman, Deniz
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
The standard treatment for operable, early stage non-small cell lung cancer (NSCLC) is surgical resection, usually lobectomy, with mediastinal lymph node sampling or dissection. However, significant surgical toxicity had been noted in these patients with 90-day mortality rates exceeding 30-day rates. There is also a risk of disease recurrence ranging from 6% to 10% per person-year during the first 4 years after surgery as stated by Lou et al. after an analysis of 1,300 patients who underwent surgery.
Source
Publisher
AME Publishing Company
Subject
Citation
item.page.haspartof
Source
Annals of Translational Medicine
item.page.ispartofseries
item.page.edition
DOI
10.3978/j.issn.2305-5839.2015.06.23
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A
